Table 1.
Baseline participant demographics
| PREVENT-AD | ADNI-1 | QFP | ||||
|---|---|---|---|---|---|---|
| CU | CU | MCI | AD | CU | AD | |
| Sample size, n | 109 | 58 | 395 | 111 | 31 | 55 |
| Mean age, years (SD) | 62.60 (5.43) | 75.11 (5.77) | 74.73 (7.40) | 74.73 (8.08) | 77.39 (11.37) | 80.71 (6.39) |
| Females, n (%) | 76 (69.72) | 28 (48.28) | 140 (35.44) | 47 (42.34) | 11 (35.48) | 23 (41.81) |
| APOE ɛ4+, n (%) | 43 (39.44) | 5 (8.62) | 210 (53.16) | 75 (67.57) | 9 (29.03) | 32 (58.18) |
| Mean BMI, kg/m2 (SD) | 27.11 (4.47) | 27.02 (4.12) | 26.09 (3.97) | 25.59 (3.82) | – | – |
| Mean HbA1c, % (SD) | 5.40 (0.40)a | – | – | – | – | – |
| Mean systolic BP, mmHg (SD) | 120.20 (13.85) | 131.41 (17.65) | 132.79 (18.14) | 135.05 (17.11) | – | – |
| Mean education, years (SD) | 14.88 (2.94)b | 15.67 (2.78) | 15.64 (3.04) | 15.09 (3.21) | – | – |
| Amyloid-positive, n (%) | 37 (33.94) | 21 (36.21) | 205 (51.90) | 91 (81.98) | 0 (0) | 55 (100) |
| Mean CSF Aβ42, pg/ml (SD) | 1145.73 (277.62)c,d | 250.85 (21.08) | 163.48 (52.90) | 142.56 (39.32) | – | – |
| Mean CSF p181-tau, pg/ml (SD) | 46.83 (18.00)c,d | 21.07 (8.43) | 36.15 (19.32) | 42.05 (19.96) | – | – |
| Mean CSF t-tau, pg/ml (SD) | 273.09 (129.97)c,d | 63.62 (21.76) | 102.33 (59.78) | 120.47 (56.58) | – | – |
| Mean CSF IGFBP2, NPX (SD) | 6.89 (0.67) | – | – | – | – | – |
| Mean CSF IGFBP2, ng/ml (SD) | – | 100.85 (15.85) | 104.93 (18.87) | 103.02 (18.76) | – | – |
| Mean plasma IGFBP2, log10 (SD) | – | 1.88 (0.20) | 1.99 (0.23) | 1.91 (0.12) | – | – |
| Mean global Aβ, SUVR (SD) | 1.30 (0.27)e | – | – | – | – | – |
| Mean tau metaROI, SUVR (SD) | 1.17 (0.07)f | – | – | – | – | – |
| Mean cortical IGFBP2, log2 (SD) | – | – | – | – | 2.43 (0.56)g | 2.50 (0.83)g |
| Mean post-mortem interval, h (SD) | – | – | – | – | 30.03 (19.85) | 21.07 (10.36) |
AD = Alzheimer's disease; ADNI = Alzheimer's Disease Neuroimaging Initiative; APOE ɛ4+ = apolipoprotein ɛ4 carriers; Aβ42 = amyloid-beta 42; BMI = body mass index; BP = blood pressure; CU = cognitively unaffected; HbA1c = haemoglobin A1c; IGFBP2 = insulin-like growth factor binding protein-2; MCI = mild cognitive impairment; NPX = Normalized Protein eXpression; p181-tau = phosphorylated tau 181; PREVENT-AD = PRe-symptomatic EValuation of Experiment or Novel Treatments for Alzheimer's disease; QFP = Quebec Founder Population (autopsy confirmed cases only, amyloid positivity dependent on plaque density); RBANS = Repeatable Battery for the Assessment of Neuropsychological Status; ROI = region of interest; SD = standard deviation; SUVR = standardized uptake value ratio; t-tau = total tau.
aOne hundred and seven participants had HbA1c values available.
bOne hundred and six participants had RBANS (Total Score) values available.
cOne hundred and one PREVENT-AD participants had CSF Aβ42, p181-tau and t-tau (pg/ml) values available.
dPREVENT-AD (Fujirebio Innotest ELISA) and ADNI (INNO-BIA AlzBio3 Immunoassay) used different assays to measure the core CSF AD biomarkers, which explains the differences.
eForty-six PREVENT-AD participants had Global Aβ SUVR values available.
fForty-nine PREVENT-AD participants had Tau metaROI SUVR values available.
gSeventy-eight QFP participants had cortical IGFBP2 protein values available.